Orum takes $8M in Se­ries A; Twist bags $27M in ven­ture fi­nanc­ing

Dae­jeon, Ko­rea-based Orum Ther­a­peu­tics closed its Se­ries A fund­ing with $8 mil­lion from In­ter­Vest, KB In­vest­ment (KBIC)/Solidus In­vest­ment, and LB In­vest­ment. “We were im­pressed with Orum’s cell-pen­e­trat­ing an­ti­body plat­form, which can trans­form an­ti­bod­ies to ef­fec­tive­ly tar­get un­drug­gable cy­toso­lic tar­gets, with­out chem­i­cal con­ju­ga­tion and with tar­get cell speci­fici­ty,” said Yeo Jung Moon, in­vest­ment di­vi­sion di­rec­tor at In­ter­vest.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.